{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026407","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.423790+00:00","generated_at":"2026-05-15T14:46:58.313323+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aclaris Therapeutics sells 5.7M shares for $20M gross proceeds in ATM offering","bullets":["5.7M shares sold on March 10, 2026 for aggregate gross proceeds of $20.0M.","Purchasers include Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP.","Sale under amended sales agreement with Leerink Partners and Cantor Fitzgerald dated Feb 27, 2025.","Gross proceeds of $20M implies average price per share of approximately $3.51."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026407","json":"https://secwatch.observer/filing/0001104659-26-026407.json","markdown":"https://secwatch.observer/filing/0001104659-26-026407.md","text":"https://secwatch.observer/filing/0001104659-26-026407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926026407/0001104659-26-026407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926026407/acrs-20260310x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:46:58.313323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}